MiNK Therapeutics, Inc. (INKT)
(Delayed Data from NSDQ)
$0.69 USD
+0.01 (2.10%)
Updated Oct 14, 2024 02:08 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INKT 0.69 +0.01(2.10%)
Will INKT be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for INKT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INKT
MiNK Therapeutics, Inc. (INKT) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for July 11th
INKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy
Other News for INKT
Analysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), MiNK Therapeutics (INKT)
MiNK Therapeutics Inc (INKT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
MiNK Therapeutics, Autonomous Therapeutics enter research collaboration
12 Health Care Stocks Moving In Friday's After-Market Session
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference